No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
Funding Information
  • Knut och Alice Wallenbergs Stiftelse (KAW 2021.0010_VC-2020-0040)
  • Vetenskapsrådet (2021-05450, 2021-03118)
  • Göran Gustafsson Foundation

This publication has 23 references indexed in Scilit: